Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar headyinvestor (61.01) Submitted: 8/15/2011 4:01:33 PM : Outperform Start Price: $7.00 EXEL Score: -44.71

I still cannot believe this dropped so significantly due to two deaths in the trials. XL-184 will be approved and this stock will skyrocket, if it isn't bought out before then.

Featured Broker Partners


Advertisement